Gilead Sciences stock has been a winner in 2020, as investors hope that one of its drugs could prove an effective treatment for Covid-19. Now the biotech firm looks one step closer to that catalyst, announcing it will start Phase 1 trials of an inhaled version of remdesivir in August.
Trending:
Gilead to begin Phase 1 trials of an inhaled version of remdesivir